$ARWR has generated 4 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on January 5, 2026. @adamfeuerstein, a biotech-focused voice, accounts for 3 of these mentions, while @investmentguru_ contributed 1 mention. The most recent discussion occurred on July 1, 2026, when @investmentguru_ included $ARWR in a broader list of 15 biotechnology stocks to watch, describing it as an "RNA interference platform targeting genetic and chronic diseases." Prior to this, @adamfeuerstein examined Arrowhead's early obesity study data in January 2026, noting concerns about the trial design and data completeness.